Table 1.

Clinical and pathologic features by tumor-infiltrating immune cell PD-1 expression for 267 patients with clear cell RCC

FeaturePD-1* (n = 190)PD-1+* (n = 77)P
Age at surgery (y)
    <65102 (53.7)36 (46.8)0.305
    ≥6588 (46.3)41 (53.2)
Sex
    Female71 (37.4)19 (24.7)0.047
    Male119 (62.6)58 (75.3)
Symptoms at presentation92 (48.4)48 (62.3)0.039
Primary tumor size (cm)
    <587 (45.8)18 (23.4)0.001
    5 to <1069 (36.3)33 (42.9)
    ≥1034 (17.9)26 (33.8)
2002 Primary tumor classification
    pT1116 (61.0)30 (39.0)0.011
    pT222 (11.6)17 (22.1)
    pT351 (26.9)29 (37.7)
    pT41 (0.5)1 (1.3)
Regional lymph node involvement8 (4.2)7 (9.1)0.143
Distant metastases at nephrectomy28 (14.7)14 (18.2)0.484
2002 Tumor-node-metastasis stage groupings
    I112 (59.0)29 (37.7)0.005
    II17 (9.0)13 (16.9)
    III33 (17.4)20 (26.0)
    IV28 (14.7)15 (19.5)
Nuclear grade
    112 (6.3)2 (2.6)0.001
    273 (38.4)17 (22.1)
    392 (48.4)42 (54.6)
    413 (6.8)16 (20.8)
Coagulative tumor necrosis46 (24.2)29 (37.7)0.027
Sarcomatoid differentiation2 (1.0)6 (7.8)0.008
Positive tumor B7-H1 expression83 (43.7)59 (76.6)<0.001
  • * Values expressed as n (%).